Vertex Pharmaceuticals IncorporatedVRTXNASDAQ
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank10
Year-over-Year Change
Year-over-year operating cash flow growth rate
Percentile
P10
Near historical low
vs 3Y Ago
-4.7x
Contraction
Streak
3 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -59.88% |
| Q3 2025 | 15.68% |
| Q2 2025 | 31.04% |
| Q1 2025 | 40.08% |
| Q4 2024 | -57.32% |
| Q3 2024 | 136.49% |
| Q2 2024 | -387.28% |
| Q1 2024 | 456.95% |
| Q4 2023 | -81.50% |
| Q3 2023 | 11.81% |
| Q2 2023 | 26.06% |
| Q1 2023 | -16.55% |
| Q4 2022 | 12.86% |
| Q3 2022 | -16.17% |
| Q2 2022 | 19.20% |
| Q1 2022 | -3.90% |
| Q4 2021 | 7.31% |
| Q3 2021 | 564.30% |
| Q2 2021 | -121.68% |
| Q1 2021 | 87.38% |
| Q4 2020 | -45.85% |
| Q3 2020 | -12.59% |
| Q2 2020 | 27.32% |
| Q1 2020 | 82.89% |
| Q4 2019 | 33.22% |
| Q3 2019 | -27.81% |
| Q2 2019 | 42.79% |
| Q1 2019 | 3.24% |
| Q4 2018 | -17.51% |
| Q3 2018 | 18.54% |
| Q2 2018 | 27.33% |
| Q1 2018 | 11.05% |
| Q4 2017 | 33.76% |
| Q3 2017 | -6.37% |
| Q2 2017 | -31.63% |
| Q1 2017 | 83.59% |
| Q4 2016 | 120.43% |
| Q3 2016 | 60.69% |
| Q2 2016 | 369.93% |
| Q1 2016 | -151.94% |